Semaglutide (GLP-1 RA) was noninferior to placebo for primary composite endpoint CV death, nonfatal MI and nonfatal stroke, overall mortality and components of primary outcome: CV death nonfatal MI and nonfatal stroke. Significant reduction in cholesterol levels and glycated hemoglobin. This evidence concerns the gene GCG and Stroke.